Files
Document type
ArticleVersion
Published versionPublication date
All rights reserved
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/147966
MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC; WNT and AKT pathways
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Ovarian cancer is the most lethal gynecological malignancy due to the silent nature on its early onset and the rapid acquisition of drug resistance. Histologically heterogeneous, it includes several subtypes with different mutational landscapes, hampering the development of effective targeted therapies. Non-coding RNAs are emerging as potential new therapeutic targets in cancer. To search for a microRNA signature related to ovarian carcinomas and study its potential as effective targeted therapy, we examined the expression of 768 miRNA in a large collection of tumor samples and found miR-654-5p to be infraexpressed in ovarian serous carcinomas, the most common and aggressive type. Restoration of miR654-5p levels reduced tumor cell viability in vitro and in vivo and impaired sphere formation capacity and viability of ovarian cancer patient-derived ascitic cells ex vivo. CDCP1 and PLAGL2 oncogenes were found to be the most relevant direct miR-654-5p targets and both genes convey in a molecular signature associated with key cancer pathways relevant to ovarian tumorigenesis, such as MYC, WNT and AKT pathways. Together, we unveiled the tumor suppressor function of miR-654-5p, suggesting that its restoration or co-targeting of CDCP1 and PLAGL2 may be an effective therapeutic approach for ovarian cancer.
Subject
Subject (English)
Citation
Citation
MAJEM, Blanca, et al. MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC; WNT and AKT pathways. Proceedings of the National Academy of Sciences of the United States of America - PNAS. 2019. Vol. 38, num. 6035-6050. ISSN 0027-8424. [consulted: 8 of June of 2026]. Available at: https://hdl.handle.net/2445/147966